Abstract Number: 3228 • 2016 ACR/ARHP Annual Meeting
Specific T Cell and B Cell Distributions Characterize Subgroups of Patients with Primary Sjögren’s Syndrome and Are Associated with Disease Activity and Pro-Inflammatory Cytokine Expression
Background/Purpose : The goal of the IMI PRECISESADS project is to reclassify individuals affected by systemic autoimmune diseases (SADs) into clusters of molecular, instead of…Abstract Number: 309 • 2015 ACR/ARHP Annual Meeting
Plasma Levels of Heat Shock Protein 90 Are Increased in Idiopathic Inflammatory Myopathies and Correlate with Disease Activity, Skeletal Muscle, Heart and Lung Involvement
Background/Purpose: Heat shock proteins (Hsps) are chaperones playing important roles in skeletal muscle physiology, adaptation to exercise or stress, and in activation of inflammatory cells.…Abstract Number: 596 • 2015 ACR/ARHP Annual Meeting
Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
Background/Purpose: Treat-to-target (T2T) in early Rheumatoid Arthritis (RA) has been successfully implemented in daily clinical practice. Patients achieve remission very early and during a follow-up…Abstract Number: 926 • 2015 ACR/ARHP Annual Meeting
Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through a Data-Driven Approach
Background/Purpose: No consensus exists regarding which joints and tendons should be systematically assessed by ultrasonography (US) to assess inflammation in rheumatoid arthritis (RA). Validity and…Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting
Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…Abstract Number: 2468 • 2015 ACR/ARHP Annual Meeting
Antibodies to Histocompatibility Antigens in Juvenile Systemic Lupus Erythematosus Patients
Background/Purpose: Microchimerism with HLA mismatched maternal cells can be readily demonstrated in normal individuals and is now established as a normal biological phenomenon. Pediatric SLE…Abstract Number: 2608 • 2015 ACR/ARHP Annual Meeting
The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission
Background/Purpose: The "Rheumatoid Arthritis Impact of Disease" (RAID) score is a Patient Reported Outcome (PRO) that comprises seven domains of disease[1], that may reflect the…Abstract Number: 2863 • 2015 ACR/ARHP Annual Meeting
Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review
Background/Purpose: In patients with axial spondyloarthritis (axSpA), anti-TNF therapy is successful for clinically improving signs and symptoms of the disease. However, there is no clear…Abstract Number: 3184 • 2015 ACR/ARHP Annual Meeting
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Background/Purpose: A Treat-to-Target approach (T2T), treating patients with RA towards a target, either remission or low disease activity (T2T-REM or T2T-LDA), is nowadays recommended. However…Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…Abstract Number: 606 • 2015 ACR/ARHP Annual Meeting
Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients
Background/Purpose: Methotrexate (MTX) and leflunomide are categorized as DMARDs of first choice in treating rheumatoid arthritis patients. MTX should be used cautiously in patients with…Abstract Number: 997 • 2015 ACR/ARHP Annual Meeting
Feasibility and Influential Factors in Performing Self-Evaluation of DAS28 with Smart System of Disease Management (SSDM) By RA Patient in China
Background/Purpose: Regular evaluations of rheumatoid arthritis (RA) disease activities with disease activity score in 28 joints (DAS28) are critical steps to reach the goal of…Abstract Number: 1689 • 2015 ACR/ARHP Annual Meeting
Cross Sectional Study Investigating the Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis
Background/Purpose: To study the effect of the presence of fibromyalgia (FMS) on common clinical disease activity indices in patients with psoriatic arthritis (PsA). Methods: Seventy…Abstract Number: 2479 • 2015 ACR/ARHP Annual Meeting
The Association Between Social Networks, Disease Activity, and Pain in Rheumatoid Arthritis
The Association between Social Network, Disease Activity, and Pain in Rheumatoid ArthritisBackground/Purpose: Current research suggests that high social network status is related to lower levels…Abstract Number: 2615 • 2015 ACR/ARHP Annual Meeting
Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity
Background/Purpose: A brief patient-reported measure of physical function, the PROMIS PF-10a, is sensitive to changes in disease activity among patients with rheumatoid arthritis (RA). However,…
- « Previous Page
- 1
- …
- 86
- 87
- 88
- 89
- 90
- …
- 112
- Next Page »
